CA1292689C - Live vaccine for contagious disease of chickens - Google Patents
Live vaccine for contagious disease of chickensInfo
- Publication number
- CA1292689C CA1292689C CA000542285A CA542285A CA1292689C CA 1292689 C CA1292689 C CA 1292689C CA 000542285 A CA000542285 A CA 000542285A CA 542285 A CA542285 A CA 542285A CA 1292689 C CA1292689 C CA 1292689C
- Authority
- CA
- Canada
- Prior art keywords
- vaccine
- virus
- chickens
- disease
- infectious laryngotracheitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 110
- 241000287828 Gallus gallus Species 0.000 title claims abstract description 93
- 235000013330 chicken meat Nutrition 0.000 title claims abstract description 92
- 201000010099 disease Diseases 0.000 title abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 16
- 208000015181 infectious disease Diseases 0.000 claims abstract description 45
- 206010044302 Tracheitis Diseases 0.000 claims abstract description 39
- 201000009837 laryngotracheitis Diseases 0.000 claims abstract description 39
- 230000002458 infectious effect Effects 0.000 claims abstract description 37
- 230000002238 attenuated effect Effects 0.000 claims abstract description 24
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 claims abstract description 21
- 208000006758 Marek Disease Diseases 0.000 claims abstract description 18
- 210000004748 cultured cell Anatomy 0.000 claims abstract description 14
- 238000010255 intramuscular injection Methods 0.000 claims abstract 2
- 239000007927 intramuscular injection Substances 0.000 claims abstract 2
- 238000010254 subcutaneous injection Methods 0.000 claims abstract 2
- 239000007929 subcutaneous injection Substances 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 46
- 208000024891 symptom Diseases 0.000 claims description 23
- 230000003053 immunization Effects 0.000 claims description 7
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 claims description 6
- 241001502481 Meleagrid alphaherpesvirus 1 Species 0.000 claims description 6
- 210000001161 mammalian embryo Anatomy 0.000 claims description 5
- 244000144977 poultry Species 0.000 claims description 4
- 235000013594 poultry meat Nutrition 0.000 claims description 4
- 241000272525 Anas platyrhynchos Species 0.000 claims description 2
- 210000003292 kidney cell Anatomy 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 2
- 241000700605 Viruses Species 0.000 abstract description 41
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000003387 muscular Effects 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 210000003837 chick embryo Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940028617 conventional vaccine Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/255—Marek's disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP170188/1986 | 1986-07-17 | ||
| JP61170188A JPS6327437A (ja) | 1986-07-17 | 1986-07-17 | 鶏伝染病生ワクチン |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1292689C true CA1292689C (en) | 1991-12-03 |
Family
ID=15900313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000542285A Expired - Fee Related CA1292689C (en) | 1986-07-17 | 1987-07-16 | Live vaccine for contagious disease of chickens |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4980162A (enExample) |
| EP (1) | EP0253389B1 (enExample) |
| JP (1) | JPS6327437A (enExample) |
| KR (1) | KR940010022B1 (enExample) |
| AT (1) | ATE86119T1 (enExample) |
| CA (1) | CA1292689C (enExample) |
| DE (1) | DE3784397T2 (enExample) |
| ES (1) | ES2053477T3 (enExample) |
| GR (1) | GR3007856T3 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5436005A (en) * | 1989-08-01 | 1995-07-25 | Arthur Webster Pty. Ltd. | Low virulence infectiouns laryngotracheitis (ILT) virus for vaccinating birds |
| AU647404B2 (en) * | 1989-08-01 | 1994-03-24 | Pfizer Australia Pty Ltd | Low virulence laryngotracheitis (ILT) virus for vaccinating birds |
| US5279965A (en) * | 1991-04-05 | 1994-01-18 | Keeler Jr Calvin L | Recombinant infectious laryngotracheitis virus |
| US5443831A (en) * | 1991-10-29 | 1995-08-22 | University Of Delaware | Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus |
| US5443982A (en) * | 1993-07-13 | 1995-08-22 | Solvay Animal Health, Inc. | Methods for the cultivation of infectious laryngotracheitis virus |
| JPH09505726A (ja) * | 1993-09-24 | 1997-06-10 | シントロ・コーポレーション | 組換え感染性喉頭気管炎ウイルス及びそれらの使用 |
| US6984728B2 (en) * | 1993-09-24 | 2006-01-10 | Schering Corporation | Recombinant infectious laryngotracheitis virus and uses thereof |
| WO1995018860A1 (en) * | 1994-01-11 | 1995-07-13 | Cornell Research Foundation, Inc. | Control of marek's disease by the inhibition of latency and tumor cell development |
| EP3727431A1 (en) * | 2017-12-20 | 2020-10-28 | Intervet International B.V. | Improved diluent for cell-associated alphaherpesvirus vaccine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3331736A (en) * | 1963-02-11 | 1967-07-18 | Schering Corp | Modified laryngotracheitis vaccine |
| US3444293A (en) * | 1964-08-24 | 1969-05-13 | Vineland Poultry Lab | Multifunctional laryngotracheitis vaccine and method of making the same |
| US3642574A (en) * | 1970-04-29 | 1972-02-15 | Us Agriculture | Method for producing vaccine for immunization of poultry against marek{3 s disease |
| US3981771A (en) * | 1973-07-19 | 1976-09-21 | Martin Sevoian | Marek's disease vaccine |
| ZA743771B (en) * | 1973-07-19 | 1975-07-30 | M Sevoian | Vaccine and preparation thereof |
| JPS57167925A (en) * | 1981-04-08 | 1982-10-16 | Handai Biseibutsubiyou Kenkyukai | Preparation of mixed vaccine for domestic fowl |
-
1986
- 1986-07-17 JP JP61170188A patent/JPS6327437A/ja active Granted
-
1987
- 1987-07-16 AT AT87110291T patent/ATE86119T1/de not_active IP Right Cessation
- 1987-07-16 KR KR1019870007688A patent/KR940010022B1/ko not_active Expired - Fee Related
- 1987-07-16 US US07/074,148 patent/US4980162A/en not_active Expired - Lifetime
- 1987-07-16 ES ES87110291T patent/ES2053477T3/es not_active Expired - Lifetime
- 1987-07-16 CA CA000542285A patent/CA1292689C/en not_active Expired - Fee Related
- 1987-07-16 DE DE8787110291T patent/DE3784397T2/de not_active Expired - Fee Related
- 1987-07-16 EP EP87110291A patent/EP0253389B1/en not_active Expired - Lifetime
-
1993
- 1993-05-14 GR GR930400341T patent/GR3007856T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE3784397T2 (de) | 1993-06-17 |
| ATE86119T1 (de) | 1993-03-15 |
| JPH0317807B2 (enExample) | 1991-03-11 |
| JPS6327437A (ja) | 1988-02-05 |
| DE3784397D1 (de) | 1993-04-08 |
| US4980162A (en) | 1990-12-25 |
| GR3007856T3 (enExample) | 1993-08-31 |
| EP0253389A1 (en) | 1988-01-20 |
| ES2053477T3 (es) | 1994-08-01 |
| EP0253389B1 (en) | 1993-03-03 |
| KR880001808A (ko) | 1988-04-27 |
| KR940010022B1 (ko) | 1994-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Calnek et al. | Field trials with a bivalent vaccine (HVT and SB-1) against Marek's disease | |
| Witter et al. | Pathogenicity of variant Marek's disease virus isolants in vaccinated and unvaccinated chickens | |
| Schat et al. | Characterisation of two highly oncogenic strains of Marek's disease virus | |
| Sharma et al. | Embryo vaccination against Marek's disease with serotypes 1, 2 and 3 vaccines administered singly or in combination | |
| Sharma | Embryo vaccination with infectious bursal disease virus alone or in combination with Marek's disease vaccine | |
| EP0996464B1 (en) | Multivalent in ovo avian vaccine | |
| Cook et al. | A live attenuated turkey rhinotracheitis virus vaccine. 2. The use of the attenuated strain as an experimental vaccine | |
| CA1292689C (en) | Live vaccine for contagious disease of chickens | |
| NZ272548A (en) | Attenuated strain of mareks disease virus (a herpes virus) and its use in poultry vaccines | |
| Friedman et al. | Marek's disease vaccines cause temporary U‐lymphocyte dysfunction and reduced resistance to infection in chicks | |
| KR100540856B1 (ko) | 뉴우캐슬병에 대한 난내 백신접종 | |
| US6451321B1 (en) | IBDV strain in ovo administration | |
| JP3410744B2 (ja) | 無細胞マレック病ウイルスワクチン | |
| Hearn Jr | A variant of Venezuelan equine encephalomyelitis virus attenuated for mice and monkeys | |
| KR920005661B1 (ko) | 생 조합 백신 | |
| US4895718A (en) | Serotype 2 Marek's disease vaccine | |
| Powell | Protection against the JMV Marek's disease‐derived transplantable tumour by Marek's disease virus‐specific antigens | |
| Lee et al. | Humoral immune responses to inactivated oil-emulsified Marek's disease vaccine | |
| Eidson et al. | Optimum age for vaccinating chickens against Marek’s disease | |
| Domermuth | Vaccination of chickens with Mycoplasma gallisepticum | |
| Eidson et al. | Resistance of progeny from parental stock of chickens immunized against Marek's disease | |
| JPH07121874B2 (ja) | 感染性気管支炎ワクチン | |
| Oei et al. | Comparison of intramuscular and subcutaneous administration of Marek's disease vaccine | |
| Geerligs et al. | efficacyofacombinatio nvaccinecontainingmdv cvi 988 strain and hvt against challenge with very virulent mdv | |
| Pruthi et al. | Efficacy of a bivalent vaccine against Marek's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |